Generative AI Patient Education Module for Breast Oncology

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT07512271
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Survey (Participant) — OTHER
    Participants will complete surveys to evaluate their experience using OpenEvidence CareConnect RAG LLM tool.
  • OpenEvidence CareConnect — OTHER
    Retrieval-Augmented Generation (RAG) Large Language Model (LLM) tool
  • Survey (Provider) — OTHER
    The provider will complete a survey to assess OpenEvidence CareConnect RAG LLM tool's usefulness and the quality of its patient education communication.

Study Details

This study evaluates the safety, accuracy, and impact of an artificial intelligence (AI) tool designed to support patient education in breast cancer care for breast oncology patients under selected physicians care within the University of California, San Francisco breast cancer center and affiliate sites.

Key Dates

Start date
May 1, 2026
Status verified
Mar 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
35 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
HEALTH_SERVICES_RESEARCH

Arms

  • Experimental: Safety Lead-in Phase
    Participants will receive access to OpenEvidence CareConnect a Retrieval-Augmented Generation (RAG) Large Language Model (LLM) tool that provides general health and breast cancer-specific information for 3 months.
  • Experimental: Interventional (Immediate Access)
    Participants will be given immediate access to OpenEvidence CareConnect for up to 3 months and complete surveys regarding use of tool. Participants are then followed up for an additional 3 months.
  • Experimental: Control (Delayed Access)
    Participants will be given access to OpenEvidence CareConnect for 3 months 90 days after enrollment

Primary Outcome Measure

Mean score of Safety and Risk Assessment (Lead-in and Provider) [ Time Frame: Up to 90 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, San FranciscoSan FranciscoCalifornia94143
Ivy Ow
[email protected]
877-827-3222
[email protected]
Michelle Melisko, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in San Francisco, CA

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
University of California, San Francisco· San Francisco, CA

Related Studies